The Guardian view on Merck’s exit: Britain’s biopharma strategy stalls in the face of China’s rise

Why is Tesla stock surging after Musk's $1B buy? What does US-China TikTok deal framework involve? How did China’s Nvidia antitrust probe impact markets? Why does Trump want to end quarterly earnings reports? How will Fed rate cut affect stock market rally? What caused Amazon’s AI-powered shopping feature launch? Why is McDonald's investing $200M in regenerative cattle farming?

The Guardian view on Merck’s exit: Britain’s biopharma strategy stalls in the face of China’s rise | Editorial

theguardian.com/commentisfree/2025/sep/15/the-guardian-view-on-mercks-exit-britains-biopharma-strategy-stalls-in-the-face-of-chinas-rise

The industry’s retreat from the UK reflects a deeper shift about how Beijing is rewriting the rules of innovation
When Merck abruptly scrapped its billion-pound London research hub last week, critics blamed Britain’s lacklustre support for life sciences and a Scrooge-like grip on NHS…

This story appeared on theguardian.com, 2025-09-15 17:45:39.